GlassScriptPhysician profile
Laveena Singla
NPI 1457702615
$3,316.08
in general payments reported to CMS, 2019-2025
15 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $44.66 · 2022: $19.96 · 2023: $184 · 2024: $2,203 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,392 · Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,391.94 |
| Food and Beverage | $1,354.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,960.01 | 2024 | |
| Ucb, INC. | $303.41 | 2023-2025 | Nayzilam |
| Sk Life Science, INC. | $226.92 | 2025 | |
| Alexion Pharmaceuticals, INC. | $187.85 | 2019-2023 | Ultomiris |
| Jazz Pharmaceuticals INC. | $171.90 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $153.20 | 2019 | |
| Emd Serono, INC. | $87.56 | 2019 | |
| Eisai INC. | $49.90 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $44.30 | 2023 | Nuedexta |
| Greenwich Biosciences, INC. | $39.74 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $25.45 | 2019 | |
| Csl Behring | $19.53 | 2024 | Hizentra |
| Pfizer INC. | $17.18 | 2019 | |
| Livanova USA, INC. | $17.07 | 2020 | |
| Acorda Therapeutics, INC | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laveena Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.